IPOs, ResMed, Ventrix, CovX, & More
Summary
The biopharmaceutical, focused on kinase-inhibiting drugs for cancer, autoimmune, and inflammatory diseases, hopes to raise $57.5 million, according to a regulatory filing.—Saying “Our society needs more heroes who are scientists and researchers and engineers,” Facebook founder Mark Zuckerberg, Google co-founder Sergey Brin, and other high-tech leaders named the first 11 recipients of the Breakthrough Prize in Life Sciences.The inaugural list includes Napoleone Ferrara, senior deputy director for basic sciences at the University of California San Diego Moores Cancer Center.—Pfizer (NYSE: PFE) said it is closing one of its R&D sites, which the world’s largest pharmaceutical company created in San Diego with its acquisition of CovX in late 2007.—Ventrix, a San Diego startup founded in 2009, said it plans to begin its first human clinical trial later this year after its VentriGel material safely and effectively improved … Next Page »
Classifications
AskAI Classifications
LabelsLinked Companies
